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he 
 
 
 
v
 
 
 
3
 
 integrin participates in cell morphogenesis,
growth factor signaling, and cell survival. Activa-
tion of the integrin is central to these processes and
is inﬂuenced by speciﬁc ECM components, which engage
both integrins and syndecans. This paper demonstrates
that the 
 
 
 
v
 
 
 
3
 
 integrin and syndecan-1 (S1) are functionally
coupled. The integrin is dependent on the syndecan to
become activated and to mediate signals required for
MDA-MB-231 and MDA-MB-435 human mammary car-
cinoma cell spreading on vitronectin or S1-speciﬁc anti-
T
 
body. Coupling of the syndecan to 
 
 
 
v
 
 
 
3
 
 requires the S1
ectodomain (ED), as ectopic expression of glycosylphos-
phatidylinositol-linked S1ED enhances 
 
 
 
v
 
 
 
3
 
 recognition
of vitronectin; and treatments that target this domain,
including competition with recombinant S1ED protein or
anti-S1ED antibodies, mutation of the S1ED, or down-
regulation of S1 expression by small-interfering RNAs,
disrupt 
 
 
 
v
 
 
 
3
 
-dependent cell spreading and migration.
Thus, S1 is likely to be a critical regulator of many cellular
behaviors that depend on activated 
 
 
 
v
 
 
 
3
 
 integrins.
 
Introduction
 
The 
 
 
 
v
 
 
 
3
 
 integrin is a key regulator of adhesion and signaling
in numerous biological processes, including tumor cell migration
and metastasis, and angiogenesis. The activated form of this
integrin participates in arrest of tumor cells in the blood stream
(Pilch et al., 2002), enhancing their extravasation to target
tissues, especially bone, where the activated integrin has further
roles in tumor cell proliferation and survival (Brooks et al.,
1994; Petitclerc et al., 1999; Eliceiri, 2001). In endothelial cells
forming new blood vessels, the active integrin is linked not
only to adhesion-dependent processes but also to signaling in
response to FGF-2 (Eliceiri et al., 1998; Hood et al., 2003).
Although 
 
 
 
v
 
 
 
3
 
 integrin expression in mammary epithelium
is low, activated 
 
 
 
v
 
 
 
3
 
 is expressed on most, if not all, successful
mammary carcinoma metastases (Liapis et al., 1996; Felding-
Habermann et al., 2001). We have reported previously that
 
 
 
v
 
 
 
3
 
 integrin on MDA-MB-231 mammary carcinoma cells
appears to be functionally linked to syndecan-1 (S1); the cells
spread when adherent to an artificial substratum comprised
solely of S1-specific antibody, and although this spreading
occurs in the absence of an 
 
 
 
v
 
 
 
3
 
 ligand, the spreading requires
activated 
 
 
 
v
 
 
 
3
 
 integrin (Beauvais and Rapraeger, 2003). This
finding suggests that even on a native ECM, anchorage of S1 to
the matrix may serve as an important regulator of 
 
 
 
v
 
 
 
3
 
 integrin
activation and signaling.
Although classically defined as a vitronectin (VN) receptor,
 
 
 
v
 
 
 
3
 
 is promiscuous and binds many ECM components including
fibronectin (FN), fibrinogen, von Willebrand Factor, proteolysed
fragments of collagen (COL), laminin (LN), osteopontin, and
others (van der Flier and Sonnenberg, 2001). Mechanisms
leading to activation of this integrin are complex, including
proteolytic cleavage (Ratnikov et al., 2002), conformational
changes (affinity modulation), and clustering (avidity modula-
tion; Carman and Springer, 2003). Activation is regulated by
“inside-out” signals from the cell interior and is stabilized by
ligand interactions that trigger “outside-in” signaling (Gian-
cotti and Ruoslahti, 1999). Cell surface receptors known to
modulate 
 
 
 
v
 
 
 
3
 
 activity include CD87/uPAR and CD47/IAP,
which associate with the 
 
 
 
3
 
 integrin subunit via their extra-
cellular domains (Lindberg et al., 1996; Xue et al., 1997) and
may also regulate 
 
 
 
v
 
 
 
3
 
 function indirectly via a pertussis-
toxin–sensitive G-protein signaling pathway (Gao et al., 1996;
Degryse et al., 2001).
The syndecan family of cell surface heparan sulfate (HS)
proteoglycans is comprised of four vertebrate members. These
receptors are expressed on virtually all cell types, although
their expression may be altered in disease states such as cancer
(Beauvais and Rapraeger, 2004). The syndecan core proteins
share a high degree of conservation in their short cytoplasmic
and transmembrane (TM) domains; in contrast, their ecto-
domains (EDs) are divergent with the exception of attach-
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ment sites for HS glycosaminoglycans. Via their HS chains,
syndecans regulate the signaling of growth factors, chemo-
kines, and morphogens and engage components of the ECM in-
cluding VN, FN, LN, tenascin, thrombospondin, and the fibril-
lar COLs (Bernfield et al., 1999).
In addition to the activities of their HS chains, the synde-
can core proteins have roles in cell adhesion signaling (Raprae-
ger, 2000; Tumova et al., 2000). Conserved and variable regions
of the syndecan cytoplasmic domains appear critical for binding
interactions that lead to adhesion-mediated signaling and reor-
ganization of the actin cytoskeleton (Couchman et al., 2001).
Important roles for the TM domain have also been demonstrated
for S1 and S4 (Tkachenko and Simons, 2002; McQuade and Ra-
praeger, 2003). Perhaps the least expected active protein domain
is the syndecan ED, which bears the HS chains. Nonetheless,
several emerging studies suggest that the syndecan ED may
have important regulatory roles in cell adhesion signaling. Cell
spreading and morphogenetic activities in COS-7 and Schwann
cells trace in part to the S1ED (Carey et al., 1994; Adams et al.,
2001). Raji cells require the S1 TM domain for initial spreading,
but depend on a S1ED activity for cell polarization (McQuade
and Rapraeger, 2003). Moreover, inhibition of ARH-77 my-
eloma and hepatocellular carcinoma cell invasion into a COL I
matrix by S1 also traces to a region of its extracellular core pro-
tein domain (Liu et al., 1998; Ohtake et al., 1999).
The activities of other syndecans also trace to their EDs.
Overexpression of syndecan-2 (S2) in COS-1 and Swiss 3T3
cells induces filipodial extension and deletion mutants of S2
map activity to the S2ED (Granes et al., 1999). Up-regulation
of S2 expression in colon carcinoma cells leads to altered cell
morphology and colony formation in soft agar; treatment with
recombinant S2ED disrupts these behaviors (Park et al., 2002;
Kim et al., 2003). Finally, activated B-lymphocytes, when
seeded on S4ED antibodies, exhibit morphological changes and
filipodial extensions. Intriguingly, only the S4ED is required
for this response, indicating that it may interact with a TM part-
ner to transmit a dendritic signal (Yamashita et al., 1999).
Our previous work in the MDA-MB-231 cells suggested
that cell spreading induced upon anchorage of the cells to a S1
antibody relies on functional coupling of the syndecan to acti-
vated 
 
 
 
v
 
 
 
3
 
 integrins (Beauvais and Rapraeger, 2003). This
spreading response is rapid (
 
 
 
15–30 min) and occurs even in
the absence of an integrin ligand (i.e., spreading is not blocked
by cycloheximide or EGTA treatment), so long as the cells are
adherent via S1. Intriguingly, the 
 
 
 
v
 
 
 
3
 
-dependent spreading
mechanism is blocked by the addition of soluble, recombinant
S1ED, suggesting that anchorage of S1 to a ligand provides a
platform for 
 
 
 
v
 
 
 
3
 
 integrin activation and adhesion signaling via
binding interaction of its ED. These findings raised a funda-
mental question about the role of S1 in ECM signaling, in par-
ticular whether or not S1 is required for 
 
 
 
v
 
 
 
3
 
 activation and
signaling in response to a native matrix ligand. Here, we show
that MDA-MB-231 and MDA-MB-435 human mammary car-
cinoma cells, which express 
 
 
 
v
 
 
 
3
 
, require S1 engagement with
the matrix for 
 
 
 
v
 
 
 
3
 
 activity on VN. Addition of recombinant
mouse S1 (mS1) ED or anti-S1ED polyclonal antibodies
(pAbs) blocks integrin activation and disrupts 
 
 
 
v
 
 
 
3
 
-dependent
spreading and migration of MDA-MB-231 and -435 cells. In
contrast, 
 
 
 
5
 
 
 
1
 
-dependent spreading and migration on FN is un-
affected by these treatments. Furthermore, we show that down-
regulation of human S1 (hS1) expression by small-interfering
RNA (siRNA) disrupts MDA-MB-231 cell spreading and mi-
gration on VN, but not on FN. Expression of a mS1 construct
containing the mS1ED alone tethered to the membrane by a
glycosylphosphatidylinositol (GPI) tail, which is unaffected by
the human-specific siRNA, rescues 
 
 
 
v
 
 
 
3
 
-dependent spreading
and migration on VN. These data suggest that S1 and the 
 
 
 
v
 
 
 
3
 
integrin are functionally coupled via the S1ED and that cou-
pling is required for 
 
 
 
v
 
 
 
3
 
 integrin activation and signaling.
 
Results
 
MDA-MB-231 cell spreading on VN is 
disrupted by soluble, recombinant S1ED
 
MDA-MB-231 human mammary carcinoma cells, plated in the
absence of serum, adhere to and spread (
 
 
 
15–20 min after plat-
ing) on wells coated with either 10 
 
 
 
g/ml VN or FN (Fig. 1).
Figure 1. MDA-MB-231 human mammary carcinoma cell spreading on
VN, but not FN, is disrupted by soluble, recombinant S1ED. Cells were
plated on wells coated with 10  g/ml VN or FN in plating medium alone
or medium containing either 30  g/ml mAb LM609, 25  g/ml mAb 13,
or 20  M GST-mS1ED or -mS4ED. Cells were incubated at 37 C for 2 h,
fixed, and stained with rhodamine-conjugated phalloidin. Bar, 50  m. 
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Cells treated with 30 
 
 
 
g/ml LM609 to block 
 
 
 
v
 
 
 
3
 
 integrins fail
to spread. LM609 has no effect on spreading in response to FN;
instead, the cells rely on 
 
 
 
5
 
 
 
1
 
 integrin to respond to FN as
spreading is blocked by either 25 
 
 
 
g/ml mAb 13 (Fig. 1; Mould
et al., 1996) or mAb 16 (Akiyama et al., 1989; unpublished
data). Our previous works have shown that 
 
 
 
v
 
 
 
3
 
 integrins are
essential for signaling when these cells are adherent to S1-spe-
cific antibody, suggesting a collaboration between these two ad-
hesion receptors even in the absence of an integrin ligand; this
collaboration between S1 and 
 
 
 
v
 
 
 
3
 
 integrins is disrupted by the
addition of recombinant GST-mS1ED (Beauvais and Raprae-
ger, 2003). To test whether or not a similar S1/
 
 
 
v
 
 
 
3
 
 collabora-
tion is at work when cells are bound to matrix, cells were plated
on either VN or FN in the presence of 20 
 
 
 
M of recombinant
GST-mS1ED. This treatment blocks cell spreading on VN but
has no effect on cell spreading on FN (Fig. 1). Treatment with
either GST alone (unpublished data) or GST-mS4ED has no ef-
fect on spreading on either ligand (Fig. 1, insets).
 
S1 adhesion–mediated cell spreading 
correlates with 
 
 
 
v
 
 
 
3
 
 integrin expression 
and activity
 
To test whether or not the 
 
 
 
v
 
 
 
3
 
 integrin’s dependence on S1
extends to other carcinoma cells, we screened a panel of hu-
man carcinoma cells with mAb LM609 using FACS analy-
sis. MDA-MB-435 cells exhibit higher 
 
 
 
v
 
 
 
3
 
 expression than
MDA-MB-231 cells, whereas MCF-7 cells are negative for this
integrin (Fig. 2 A). To test the collaboration between S1 and
 
 
 
v
 
 
 
3
 
 integrin when cells are adherent via S1, MDA-MB-435
and MCF-7 cells were plated on wells coated with hS1-spe-
cific mAb B-B4. Although 
 
 
 
v
 
 
 
3
 
-positive MDA-MB-435 cells
spread on this antibody substratum, their spreading is blocked
(Beauvais and Rapraeger, 2003) by treatment with either mAb
LM609 (added either before plating or 30 min after plating,
when cells have already begun to spread) or GST-mS1ED pro-
tein (which is not recognized by mAb B-B4). MCF-7 (Fig. 2 B)
and T47D (unpublished data) cells, which are 
 
 
 
v
 
 
 
3
 
 negative,
bind to mAb B-B4 but fail to spread.
To verify that cell spreading induced upon S1 ligation
correlates with 
 
 
 
v
 
 
 
3
 
 activation, we relied on binding of the
ligand-mimetic WOW1 mouse Fab, a probe that detects acti-
vated but unligated 
 
 
 
v
 
 3 integrin. MDA-MB-435 cells adherent
to mAb B-B4 display strong binding of WOW1 both centrally
and within puncta at the spreading margin of cells (Fig. 2 C). In
contrast, WOW1 fails to bind to cells treated with 20  M GST-
mS1ED, and this correlates with the failure of the cells to
spread (Fig. 2 C, phase insets). WOW1 also binds to MDA-
MB-231 cells adherent to mAb B-B4 and pretreated with mAb
13 before plating; treatment with mAb 13 relieves a negative
 1- 3 integrin cross-talk mechanism active in the MDA-MB-
231 cells, thus allowing for  v 3 integrin activation (Beauvais
and Rapraeger, 2003). Like the MDA-MB-435 cells, WOW1
staining is also lost from the MDA-MB-231 cells when cells
are treated with 20  M GST-mS1ED. As a control, WOW1
fails to bind MDA-MB-435 or MB-231 cells adherent and
spread on COL I, a  1 integrin–specific ligand. This finding
agrees with growing evidence that activation of certain  1 inte-
Figure 2. S1 adhesion–mediated cell spreading correlates with  v 3
integrin expression and activity. (A) FACS analysis of  v 3 integrin expres-
sion (mAb LM609) in human mammary carcinoma cells against an IgG
isotype control. (B) Depicted on split panels are phalloidin-stained MDA-MB-
435 (top) and MCF-7 (bottom) cells 2 h after plating on wells coated with
mAb B-B4 in plating medium alone or medium containing either 30  g/ml
mAb LM609, 1  g/ml mAb 13, or 20  M GST-mS1ED. Bar, 50  m. (C)
Untreated MDA-MB-435, MDA-MB-231, and MCF-7 cells (first and last
columns) and cells pretreated in suspension with 1  g/ml mAb 13 (middle
columns) were seeded on wells coated with either mAb B-B4 or COL I in
plating medium alone (first, second, and last columns) or medium containing
20  M GST-mS1ED (third column). Cells were incubated at 37 C for 2 h,
fixed, permeabilized, and stained with WOW1 and an Alexa 488–conju-
gated secondary antibody. Panel insets are corresponding phase-contrast
pictures. Bar, 20  m.JCB • VOLUME 167 • NUMBER 1 • 2004 174
grins can down-regulate  v 3 integrin activity in several cell
lines (Kim et al., 2000; Kiosses et al., 2001; Gonzalez et al.,
2002; Beauvais and Rapraeger, 2003). We do not see WOW1
binding to the  v 3-negative MCF-7 cells.
MDA-MB-435, but not MCF-7, human 
carcinoma cells display functional 
coupling of S1 and  v 3 integrin on VN
To test if  v 3 integrin activation on an ECM ligand is also
functionally coupled to S1, MDA-MB-435 and MCF-7 cells
were plated on either VN or FN (Fig. 3). MDA-MB-435 cells
spread on VN and require  v 3 integrins for this activity as
spreading is blocked by mAb LM609. Although the MCF-7
cells spread on VN, this spreading is unaffected by LM609;
these cells rely instead on  v 1 integrins as spreading is
blocked by either mAb 13 (Fig. 3) or  v-specific mAb M9 (de
Vries et al., 1986). Neither cell type uses  v 3 to respond to
FN, rather both use  5 1 integrins that are blocked by either
mAb 13 (Fig. 3) or mAb 16 (unpublished data).
To test whether or not GST-mS1ED specifically blocks
 v 3 integrin–dependent spreading or acts as a general inhibi-
tor to all  v integrin heterodimers, MDA-MB-435 and MCF-7
cells were plated on VN in the presence of 20  M GST-
mS1ED. Only the MDA-MB-435 cells fail to spread in re-
sponse to VN after treatment with GST-mS1ED, although they
retain their ability to spread on FN. This effect appears specific
for S1ED as treatment with GST alone or GST-mS4ED (un-
published data) has no effect.
Polyclonal S1ED antibodies disrupt  v 3 
integrin–dependent cell spreading and 
migration on VN
To target the syndecan directly, MDA-MB-231 and MB-435
( v 3-positive) cells were treated with S1ED-specific pAb
before plating. The pAb recognizes S1 on blots and live cells,
but fails to recognize other syndecan family members (unpub-
lished data). The cells display a dose-dependent inhibition in
VN-dependent cell spreading over a pAb concentration range
of 10–250  g/ml (Fig. 4). The number of spread cells (diame-
ter  20  m) on VN was reduced from 92   6% in the ab-
sence of pAb to 30   4% at 100  g/ml pAb with almost com-
plete inhibition ( 7%) for both cell types at 250  g/ml. Note
that the treatment of either cell type with pAb does not alter
their spreading in response to FN. The relatively high pAb
concentration required to achieve full inhibition of spreading
may indicate that the “blocking” antibody is a relatively mi-
Figure 3. MDA-MB-435, but not MCF-7, human carcinoma cells display
functional coupling of S1 and  v 3 integrins on VN. Depicted are phalloidin-
stained cells 2 h after plating on wells coated with 10  g/ml VN (top half
of panels) or FN (bottom half) in plating medium alone or medium contain-
ing either 30  g/ml mAb LM609, 25  g/ml mAb 13, or 20  M GST-
mS1ED or -mS4ED. Bar, 50  m.
Figure 4. Polyclonal S1ED antibodies disrupt  v 3 integrin–dependent
cell spreading on VN. MDA-MB-231 and -435 cells were plated on wells
coated with 10  g/ml VN (top half) or FN (bottom half) in plating medium
alone or medium containing 10, 100, or 250  g/ml of anti-mS1ED pAb.
Cells were incubated at 37 C for 2 h, fixed, and stained with rhodamine-
conjugated phalloidin. Bar, 50  m.SYNDECAN-1 REGULATES  V 3 INTEGRIN ACTIVITY • BEAUVAIS ET AL. 175
nor fraction of the pAb mix. Treatment of cells with 250  g/
ml of anti-GST pAb has no effect on cell spreading on either
matrix ligand (unpublished data).
To test the role of the S1ED in  v 3 integrin–dependent
signaling in another functional assay, cells were examined for
their ability to migrate across VN- or FN-coated filters in the
presence or absence of S1ED pAb (250  g/ml) or GST-
mS1ED recombinant protein (20  M). Migration of treated
MDA-MB-231 and MB-435 cells across VN is suppressed
two- to fourfold relative to untreated controls (Fig. 5 A). MCF-7
cell migration across VN, which is  v 1 dependent, is unaf-
fected by either treatment. Furthermore, neither inhibitor has
any effect on cell migration across FN in any of the three cell
types tested (Fig. 5 B).
Activity resides within the ED of the S1 
core protein
To confirm that the S1ED is necessary and sufficient for the ac-
tivation of  v 3 integrin–dependent cell spreading, MDA-MB-
231 cells were transfected with mS1 expression constructs
(Fig. 6 A). Populations of high-expressing clones were sorted
by FACS analysis using mAb 281.2, an antibody that selec-
tively recognizes mS1, to ensure comparable levels of expres-
sion. Cells were then plated on S1-specific antibodies to assess
their ability to spread in response to S1 ligation.
NEO (pcDNA3 empty vector) cells (Fig. 6 B) adherent to
hS1-specific antibody mAb B-B4 fail to spread unless treated
with mAb P5D2, a  1 integrin–neutralizing antibody (Fig. 6,
NEO, inset), that relieves an  2 1-dependent repression of  v 3
integrins (Beauvais and Rapraeger, 2003). To test the activity
of the mS1 constructs, cells were plated on mAb 281.2. Inter-
estingly, cells expressing full-length mS1 spread (Fig. 6 B,
Figure 5. S1ED inhibitors disrupt  v 3 integrin–dependent cell migration
on VN. MDA-MB-231, MDA-MB-435, and MCF-7 cells in plating medium
alone (black) or in plating medium containing either 20  M GST-mS1ED
(white) or 250  g/ml mS1ED pAbs (gray) were seeded on polycarbonate
filters coated with either 10  g/ml VN (A) or FN (B) in a modified Boyden
chamber. After 16 h, cells that migrated through the filter in response to
10% FBS in the lower chamber were quantified by colorimetric staining.
The error bars represent the SEM from three independent experiments.
Figure 6. Deletion of a region of the S1ED blocks  v 3-mediated cell
spreading. (A) Graphic representation of S1 expression constructs trans-
fected into MDA-MB-231 cells and their relative expression levels as
detected by FACS (mean fluorescent intensity). Asterisks indicate the HS
attachment sites. (B) Cells transfected with empty vector (NEO) or S1 con-
structs were seeded in plating medium on wells coated with either anti-hS1
mAb B-B4 (NEO   inset, hS1, and insets of mS1) or anti-mS1 mAb 281.2
(all others). Where noted, cells were pretreated in suspension with 1  g/ml
mAb P5D2 for 15 min before plating. Cells were incubated at 37 C for 2 h,
fixed, and stained with rhodamine-conjugated phalloidin. Bar, 50  m.JCB • VOLUME 167 • NUMBER 1 • 2004 176
mS1) without prior inhibition of  1. This response is not unique
to mS1, as hS1-overexpressors (Fig. 6 B, hS1), when plated on
mAb B-B4, also spread in the absence of  1 integrin blockade,
suggesting that overexpression of S1 overcomes the negative
 1- 3 integrin cross-talk mechanism in these cells. Intriguingly,
mS1-overexpressing cells fail to spread on mAb B-B4 unless
cells are treated with the  1 blocker (Fig. 6, mS1, insets) mim-
icking the response of NEO cells plated on a similar substratum
(Fig. 6 B, NEO). Thus, endogenous hS1 and ectopic mS1 ap-
pear to act independently of each other and the cells respond
only to the ligated S1.
To identify the properties of S1 required to regulate  v 3
integrin activity, cells expressing mS1 mutants were plated on
a substratum of mAb 281.2. A mutant that lacks its HS chains
(mS1
TDM) retains its ability to spread. Cells expressing a S1
construct that lacks either its cytoplasmic domain (mS1
 280-311)
or both its TM and cytoplasmic domains (GPI-mS1ED) re-
tain their ability to spread, confirming that activity resides in
the S1ED. Mutants with progressively larger ED deletions
(mS1
 223-252, mS1
 202-252, and mS1
 147-252) all retain activity (un-
published data) as does a S1 construct (mS1
 122-252) that lacks
131 amino acids located between the HS attachment sites and
the TM domain. However, cells expressing a mutant (mS1
 88-252)
that lacks 34 additional amino acids, fail to spread; and spread-
ing cannot be rescued by treatment with mAb P5D2 (Fig. 6,
mS1
 88-252, inset), a treatment that would have otherwise en-
hanced  v 3 integrin activation (Fig. 6, NEO, inset).
Overexpression and ligation 
of S1 “primes” cells to spread 
in response to VN
To test if overexpression of S1 enhances VN recognition via
the  v 3 integrin, cell attachment and spreading were assessed
on wells containing increasing concentrations of VN (1, 3, and
10  g/ml; Fig. 7 A). NEO control cells largely fail to bind to
wells coated with 1  g/ml VN and display only modest spread-
ing in response to 3  g/ml. Full adhesion and spreading is
not achieved until cells encounter high concentrations of VN
(10  g/ml). In contrast, cells overexpressing the S1ED (GPI-
mS1ED) attach and spread on low VN concentrations and this
response increases with higher concentrations of VN. How-
ever, this response is dependent on S1’s engagement of the ma-
trix as cells expressing mS1
TDM (which lacks its HS chains)
mimic the response of NEO control cells.
These results correlate with the induction in  v 3 activa-
tion observed when cells are adherent to S1 antibody (Fig. 2 C)
and suggest that  v 3 activation depends on S1 being engaged
by ligand. To test this, integrin activation and expression was
examined in S1-overexpressing cells in suspension (  mS1
clustering) and when adherent to S1 antibody. On suspended
cells when mS1 is not clustered, we detect no increase in  v 3
activity (Fig. 7 D, WOW1). However, when mS1 is clustered
using mAb 281.2, although we detect no change in  v 3 ex-
pression (Fig. 7 B, mAb LM609), we do detect a demonstrable
increase in  v 3 activity with either mS1 or GPI-mS1ED (un-
published data), but not with mS1
 88-252 (Fig. 7 E, WOW1). Ac-
tivation of the integrin with 1.0 mM Mn
2  (Smith et al., 1994;
Figure 7. Overexpression and ligation of S1 activates  v 3 integrins
and primes cells to spread on VN. (A) MDA-MB-231 cells transfected
with empty vector (NEO), GPI-mS1ED, or mS1
TDM were seeded on wells
coated with 1, 3, or 10  g/ml VN. Cells were incubated at 37 C for 2 h,
fixed, and stained with rhodamine-conjugated phalloidin. Bar, 50  m.
(B–E) Suspended cells in which mS1 was clustered (mAb 281.2, B and E)
or not clustered (mAb KY8.2, C and D) were fixed and labeled with mAb
LM609 (B) or WOW1 mouse Fab (C–E) followed by an Alexa 488–conju-
gated secondary antibody and analyzed by FACS. As controls for
WOW1 staining (C), suspended cells were incubated with plating me-
dium alone (black-filled histogram), plating medium containing 1 mM
MnCl2 (right-shifted histogram), or divalent cation-free PBS (left-shifted his-
togram) before fixation and staining. (F) Cells were seeded on wells
coated with either mAb B-B4 or 281.2, incubated at 37 C for 2 h, fixed,
permeabilized, and stained with WOW1 and an Alexa 488–conjugated
secondary antibody. Panel insets are corresponding phase-contrast pic-
tures. Bar, 20  m.SYNDECAN-1 REGULATES  V 3 INTEGRIN ACTIVITY • BEAUVAIS ET AL. 177
Lin et al., 1997; Pampori et al., 1999) is shown for comparison
(Fig. 7 C); this contrasts with the diminished WOW1 binding
observed following inactivation of the integrin by the removal
of divalent cations (Fig. 7 C, CMF-PBS).
Although enhanced S1 expression has no effect on  v 3
activation levels on suspended cells (Fig. 7 D), a different re-
sult is obtained when the cells are assessed in antibody-based
adhesion assays (Fig. 7 F). Cells overexpressing hS1 or mS1
stain positively with WOW1 when adherent to their respective
S1-specific antibodies, whereas NEO cells bound to B-B4 dis-
play no significant WOW1 binding. However, cells overex-
pressing mS1 fail to bind WOW1 when adherent via their en-
dogenous hS1 (B-B4), indicating again that the syndecan must
be ligated to efficiently activate the  v 3 integrin. Cells overex-
pressing mS1
 122-252, a S1ED mutant that retains its ability to
signal spreading in response to S1 ligation (Fig. 6 B), also dis-
play positive staining for WOW1, but cells overexpressing
mS1
 88-252, a mutant which fails to signal spreading, do not.
Down-regulation of S1 expression by 
siRNA disrupts cell spreading and 
migration in response to VN
To test the activity of the mS1 mutants on matrix ligands, the
expression of the endogenous hS1 needs to be blocked. Thus,
cells expressing mS1 constructs were transfected with siRNA
designed to specifically target hS1 (Fig. 8 A). Transfection
with siRNA efficiently silences hS1 ( 90% reduction) in both
NEO vector-control cells (Fig. 8 B) and in cells expressing
Figure 8. Down-regulation of S1 expression by siRNA disrupts cell spreading and migration on VN. (A) SiRNA targeting of hS1 mRNA. FACS analysis
for (B and C) hS1 (mAb B-B4), (D) hS4 (mAb F94-8G3), and (E) mS1 (mAb 281.2) expression against IgG controls (black-filled histograms) in NEO- and
GPI-mS1ED–expressing MDA-MB-231 cells 72 h after transfection with either lipid-vehicle alone (Vehicle or (V)) or 200 nM siRNA (RNAi or (R)). (F)
NEO
MDA-MB-231 cells and MDA-MB-231 cells expressing GPI-mS1ED, mS1
 88-252, mS1
 122-252, and mS1
TDM were transfected with lipid-vehicle alone or 200 nM
hS1-siRNA and seeded on wells coated with either 10  g/ml VN or FN. Cells were incubated at 37 C for 2 h, fixed, and stained with rhodamine-conjugated
phalloidin. Bar, 50  m. (G and H) Lipid-vehicle (gray) or hS1-siRNA (black) transfected cells were also plated on polycarbonate filters coated with either
10  g/ml VN (G) or FN (H) in a modified Boyden chamber. After 16 h, cells that migrated through the filter in response to 10% FBS in the lower chamber
were quantified by colorimetric staining. The error bars represent the SEM from three independent experiments.JCB • VOLUME 167 • NUMBER 1 • 2004 178
mS1 constructs (GPI-mS1ED provided as a representative re-
sult; Fig. 8 C). Importantly, hS1 siRNA affects neither mS1 ex-
pression (Fig. 8 E) nor the expression of hS4 in either NEO
vector control or mS1-expressing cells (Fig. 8 D). In addition,
hS1 siRNA has no effect on the expression levels of either  v 3
or  1 integrins as determined by FACS (unpublished data).
NEO vector control cells lacking hS1 fail to spread in re-
sponse to VN, but are able to spread on FN. Cell spreading on
VN is recovered by expression of GPI-mS1ED (Fig. 8 F) and
mS1
 122-252 (unpublished data). It is unlikely that the siRNA
treatment has any nonspecific cellular effects because spreading
is specifically rescued by expression of GPI-mS1ED. However,
spreading is not recovered in cells expressing mS1
 88-252, the
S1ED mutant that fails to signal spreading in S1 antibody–based
adhesion assays. Cells expressing mS1
TDM, a mutant unable to
engage the matrix, also fail to spread on VN, confirming that
S1-mediated adhesion is required for full  v 3 integrin activity.
To test the effects of hS1 silencing on cell migration, the
migration of hS1 siRNA-transfected cells was examined on
VN- or FN-coated filters. Migration of the NEO cells across
VN is reduced approximately threefold by siRNA relative to
untreated controls (Fig. 8 G). In addition, cell migration in re-
sponse to VN is rescued in the siRNA-treated cells by expres-
sion of GPI-mS1ED or mS1
 122-252, but not by mS1
TDM or
mS1
 88-252. None of the cells display any defects in their ability
to migrate in response to FN (Fig. 8 H).
Discussion
The current study demonstrates a functional coupling between
the  v 3 integrin and S1 that regulates the activation and signal-
ing of the integrin during carcinoma cell spreading and migra-
tion. Whether this functional coupling is via a signaling pathway
or via a direct interaction between these two receptors is not yet
known; however, we do describe several features of this mecha-
nism. First, S1-dependent activation of  v 3 is contingent on the
syndecan engaging a ligand. On antibody, ligation of S1 devoid
of HS leads to integrin activation and cell spreading, the latter
using integrin-mediated signaling in the absence of an integrin
ligand. On VN, a ligand that engages both S1 and  v 3, the inte-
grin activation requires S1 bearing its HS chains, presumably to
engage the heparin-binding domain of VN.
The finding that ligation of S1 is not only necessary but
seemingly sufficient for integrin activation, as occurs on S1 an-
tibody, is surprising. Most, if not all, ECM ligands have hepa-
rin binding domains that presumably engage S1; yet, the  v 3
integrin is not always active on these matrices. An example is
the cell behaviors that we observe on FN, where  5 1 signaling
predominates; the  v 3 integrin is inactive despite the fact that
it (Charo et al., 1990) and S1 can engage the FN. Thus, unlike
the antibody substratum, recognition of ECM components by
other integrins and syndecans may disrupt the syndecan- v 3
coupling mechanism or target the  v 3 directly, thus defeating
S1 and inactivating the integrin.
In the MDA-MB-231 cells, the  v 3 integrin is main-
tained in an inactive state by negative cross-talk, apparently from
the  2 1 integrin (Beauvais and Rapraeger, 2003). When cells
are plated on S1 antibody, this cross-talk mechanism prevents
 v 3 integrin activation; however, expression of higher S1 levels
overrides the competing inhibition from the  2 1 integrin as long
as S1 is ligated. Overexpression of mS1 will not lead to integrin
activation if the cells are adherent only via their endogenous hS1,
indicating that hS1 and mS1 act independently and are unlikely
to multimerize. A similar “priming” of integrin activation due to
enhanced S1 expression drives  v 3-dependent adhesion and
spreading on low concentrations of VN—levels at which paren-
tal cells cannot respond. It is worth noting that increased S1 ex-
pression in breast carcinomas and melanomas correlates with an
aggressive metastatic phenotype and poor clinical prognosis (Ti-
mar et al., 1992; Barbareschi et al., 2003; Burbach et al., 2003);
this finding may trace to up-regulation in  v 3 activity.
A second feature of the coupling mechanism is its reli-
ance on the S1ED. Regardless of whether S1 is engaged by an-
tibody or VN, integrin activation is blocked by treatments that
target this domain, including competition with anti-S1 antibod-
ies or recombinant S1ED. Furthermore, inactivation of the inte-
grin seen upon siRNA-dependent inhibition of hS1 expression
is overcome by expression of GPI-linked mS1ED. Admittedly,
the inhibitory effects of these reagents on cell spreading and
migration on VN was a surprise. Unlike the S1 antibody–based
adhesion assays, cells on VN are clearly provided an  v 3 inte-
grin ligand, yet even in the presence of this ligand, the integrin
still requires S1 in order to signal, indicating a potentially im-
portant role for the S1ED that extends beyond the initial activa-
tion of the integrin. Although further experimentation will be
necessary to identify the active site, a syndecan mutant lacking
amino acids 121–252 of the ED retains activity, whereas one
lacking an additional 34 amino acids ( 88–252) does not. Im-
portantly, within this 34–amino acid stretch mS1 and hS1 share
58% identity and 72% homology, indicating that activity of the
S1ED is likely conserved between the species. This is also evi-
denced by the fact that overexpression of either S1 species is
sufficient to confer enhanced  v 3 activity.
Other studies have implicated the syndecan EDs in im-
portant protein interactions at cell surfaces. S1- and S4EDs me-
diate binding interactions with cultured fibroblasts and endo-
thelial cells (McFall and Rapraeger, 1997, 1998). Antibodies
that target the EDs of S1 and S3 block Schwann cell spreading
on LN and FN (Carey et al., 1994) and FGF2-dependent prolif-
eration of cultured chondrocytes (Kirsch et al., 2002), respec-
tively. Competition with recombinant ED is effective in dis-
rupting cell spreading and inducing cell cycle arrest in colon
carcinoma cells that overexpress S2 (Park et al., 2002). Finally,
polarization of S1-expressing Raji cells is dependent on the
S1ED (McQuade and Rapraeger, 2003). In each of these cases,
the exact mechanism of the extracellular core protein interac-
tion remains unknown.
A third feature of the coupling mechanism is that it is
specific for the  v 3 integrin. MCF-7 cells spread and migrate
on VN, but use the  v 1 integrin. S1 is not required for the ac-
tivity of this integrin, nor is it inactivated by any treatments that
target S1. Similarly, cell spreading and migration on FN, which
requires  5 1 integrin activity, appears to occur independent of
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specific for S1. Coupling is not observed in MDA-MB-231
cells adherent via S4 (i.e., treatment with mAb LM609 has no
effect on cells adherent and spread on S4 antibody, mAb 150.9)
nor in cells adherent to mAb RVS-10, an anti-CD71/transferrin
receptor antibody (unpublished data). CD71-adherent cells fail
to spread even in the presence of a function-blocking  1 inte-
grin antibody that stimulates spreading in cells adherent via S1
(Beauvais and Rapraeger, 2003).
Multiple mechanisms, including affinity and avidity modu-
lation, regulate integrin function. Affinity modulation of  v 3 is
complex and involves conformational changes within its extra-
cellular domain (Beglova et al., 2002; Takagi et al., 2002). This
process is regulated by inside-out signaling that impinges on the
integrin’s cytoplasmic domains either by stimulating proteolysis
(Du et al., 1995; Smith, 1997), phosphorylation (Blystone et al.,
1996; Jenkins et al., 1998), or binding of intracellular proteins
such as talin (Calderwood et al., 1999, 2002) and  3-endonexin
(Shattil et al., 1995; Kashiwagi et al., 1997). These intracellular
events lead to the exposure of ligand-binding epitopes in the in-
tegrin’s extracellular domains (Hughes et al., 1996). Studies on
VN suggest that  v 3 can assume two or more distinct activation
states (Takagi et al., 2002), and distinct  v 3 conformations have
been detected for different matrix ligands (Boettiger et al., 2001).
Ligand binding, in turn, stabilizes structural changes that initiate
outside-in signaling that include tyrosine phosphorylation of the
 3 cytoplasmic tail (Schaffner-Reckinger et al., 1998; Law et al.,
1999) and association of the  3 subunit cytoplasmic tail with in-
tracellular effectors.
Although interactions of  v 3 with extracellular ligands
stimulate outside-in signaling, signaling via unligated  v 3 is
important in a process known as “integrin-mediated death”
(IMD; Stupack et al., 2001). In cells sensitive to IMD,  v 3 may
act as a sensor during cell invasion, inducing cell death when the
cells encounter a nonpermissive ECM (Ilic et al., 1998). Until
now, it has been unclear whether or not unligated  v 3 integrins
can participate in cell signaling processes other than IMD. How-
ever, in this work, the unligated  v 3 is capable of transmitting
signals that lead to cell spreading when S1 is engaged. It is ap-
pealing to speculate that S1 via its adhesion-dependent activa-
tion of  v 3 may act as a negative regulator of IMD.
 v 3 integrins interact with several cell surface recep-
tors including PDGFR-  and VEGFR-2 (Borges et al., 2000),
CD87/uPAR (Wei et al., 1996), and CD47/IAP (Lindberg et
al., 1996; Fujimoto et al., 2003) via the  3 extracellular do-
main. It is possible that S1 also engages directly with the inte-
grin or with one of these other receptors. Like CD47, we find
that the S1ED, when expressed in cells and engaged with
ligand, is sufficient to mediate a functional interaction with
the  3 subunit that alters the conformation of the integrin to a
high affinity ligand binding state. However, soluble recombi-
nant S1ED, which is not tethered to the membrane and unable
to sense the mechanical force imbued by an immobilized
ligand, acts as a functional inhibitor of  v 3. Intriguingly, sol-
uble recombinant CD87 binds to the  v 3 integrin (Degryse et
al., 2001) and competitively inhibits the physical and func-
tional coupling of CD87 to the integrin (Wei et al., 1996; Si-
mon et al., 2000).
Why must the syndecan be anchored? Anchorage of the
syndecan to an immobilized ligand may cluster the syndecan
and/or induce conformational changes in the S1ED. These
changes may induce clustering of the integrin itself or enhance
signaling required for  v 3 activation. Our data support a role
in affinity modulation (e.g., WOW1 binding), although avidity
modulation may take place as well.
In summary, this work highlights a novel mechanism in
which the activity and function of the  v 3 integrin is directly
modulated by its physical or functional coupling to S1. As
such, S1 is likely to be a critical regulator of  v 3 integrin in
the multiple cell behaviors that rely on this integrin.
Materials and methods
Reagents 
Matrix ligands include human plasma FN (provided by D. Peters, Univer-
sity of Wisconsin, Madison, WI) and VN (Promega) and type I COL (BD
Biosciences). Mouse mAbs B-B4 (Wijdenes et al., 1996), F94-8G3 (David
et al., 1992), RVS-10 (Chemicon), rat mAbs 281.2 (Jalkanen et al.,
1985), and KY 8.2 (Yamashita et al., 1999) recognize hS1, hS4, CD71/
transferrin receptor, mS1, and mS4, respectively. Integrin antibodies in-
clude the following:  1 and  5 1 inhibitory mAb 13 and mAb 16 (pro-
vided by S. Akiyama, National Institute of Dental Research, Bethesda,
MD),  1 inhibitory mAb P5D2,  v inhibitory mAb M9, and  v 3 inhibitory
mAb LM609 (Chemicon). The ligand-mimetic Fab WOW1 (provided by
S. Shattil, Scripps Research Institute, La Jolla, CA) was used to detect acti-
vated  v 3 integrin (Pampori et al., 1999).
Recombinant GST–fused mS1ED (GST-mS1ED) and S4ED (GST-
mS4ED) protein was prepared as described previously (McFall and Ra-
praeger, 1998). GST-mS1ED was used as an antigen in New Zealand
white rabbits, and antibodies were affinity-purified by sequential GST-
mS1ED and GST columns (Harlow and Lane, 1988).
Cell culture and transfection
MDA-MB-231, MDA-MB-435, and MCF-7 human carcinoma cells were
grown in DME (Life Technologies) supplemented with 10% FBS (Hyclone
Laboratories), 4 mM L-glutamine (Sigma-Aldrich), and 100 U/ml penicillin
and 100  g/ml streptomycin (Life Technologies) at 37 C and 92.5% air/
7.5% CO2. Growth medium for MCF-7 cells was additionally supple-
mented with 10  g/ml of bovine pancreatic insulin (Sigma-Aldrich).
Syndecan cDNA constructs (provided by R. Sanderson, University
of Arkansas for Medical Sciences, Little Rock, AR) in vector pcDNA3 (Invi-
trogen) have been previously described (Langford et al., 1998; Liu et al.,
1998; McQuade and Rapraeger, 2003). MDA-MB-231 cells were trans-
fected using LipofectAMINE PLUS (Invitrogen) and 10  g of plasmid in ac-
cordance with the manufacturer’s instructions. Stable populations express-
ing high but equal levels of ectopic S1 were selected in 1.5 mg/ml G418
(GIBCO BRL) and sorted by FACS.
siRNA design and transfection 
Three siRNAs (nucleotide annotation: 
874AGGACTTCACCTTTGAAACC
893,
1162AGGAGGAATTCTATGCCTGA
1181, and 
1749GGTAAGTTAAGTAAGT-
TGA
1767 [GenBank/EMBL/DDBJ accession no. NM_002997]) specific for
hS1 were designed by Ambion; each silences hS1 expression by  90%.
For transfection, 200 nM siRNA was added to 2.0   10
5 cells in 35-mm
wells using LipofectAMINE2000 and Opti-MEM I transfection medium (Invi-
trogen) lacking serum and antibiotics. Control cells were transfected with
lipid-based vehicle alone. At 4 h after transfection, each well was supple-
mented with 3 ml of complete growth medium; at 24 h after transfection the
cells were lifted in trypsin (0.25% wt/vol) and expanded in 100-mm tissue-
culture plates. Cells were harvested 72 h after transfection and experimental
cohorts subjected to two-color FACS analysis.
Cell spreading assays
Nitrocellulose-coated 10-well glass slides (Erie Scientific) were prepared
as described previously (Lebakken and Rapraeger, 1996). Wells were
coated with ligands at 37 C for 2 h. mAbs 281.2 and B-B4 (10  g/ml),
diluted in calcium and magnesium-free PBS (CMF-PBS, 135 mM NaCl,
2.7 mM KCl, 10.2 mM Na2HPO4 · 7H2O, and 1.75 mM KH2PO4, pH
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of goat anti–rat or anti–mouse IgG, respectively (Jackson ImmunoResearch
Laboratories). 10  g/ml FN, 10  g/ml COL I, or 1–10  g/ml VN were
heated to 37 C for 15 min, diluted in serum-free 15 mM Hepes-buffered
(Hb) DME, pH 7.4, and coated directly to wells. Wells were blocked with
serum-free Hb-DME containing 1.0% heat-denatured BSA (plating me-
dium) for 1 h at 37 C. Cells were lifted in Tris-EDTA-saline (20 mM Tris,
pH 7.5, 165 mM NaCl, and 5 mM EDTA), washed with plating medium,
and plated on wells (50  l per well) in the same medium (  inhibitors) at
a cell density of 4.0   10
5 cells per milliliter. Where syndecan mAb was
used as a substratum, the plating medium was supplemented with 0.2 U/ml
of heparinase mix (heparinase I, II, and III) and 0.05 U/ml chondroitin
ABC lyase (Seikagaku America) to enzymatically remove glycosaminogly-
cans. Cells were allowed to adhere and spread for 2 h at 37 C, followed
by washing in CMF-PBS and fixation for 2 h in 2% PFA at 4 C.
Cell staining and quantification of spreading
Fixed cells were stained with rhodamine-conjugated phalloidin as de-
scribed previously (Lebakken et al., 2000). Alternatively, cells were stained
with WOW-1 Fab (1:4 dilution) diluted in Hepes tyrode buffer (Beauvais
and Rapraeger, 2003) for 1 h at 37 C followed by Alexa-488–conjugated
goat anti–mouse IgG (H L) F(ab’)2 secondary antibody (Molecular Probes).
Slides were mounted with a coverslip in aqueous, non-fluorescing mounting
medium (Immu-mount; Thermo Shandon). All images were acquired at RT
with a 20  Fluor objective (0.75 NA; Nikon), with the exception of a 63 
Planapo objective (1.4 NA; Carl Zeiss MicroImaging, Inc.) for Fig. 7 F, on
a microscope (model Microphot-FX; Nikon) and attached Image Point Sci-
entific cooled CCD camera (Photometrics), using Image-Pro Plus version 1.3
(Nikon). Images were processed (cropping, contrast, and size adjustments)
in Adobe Photoshop version 7.0. All images represent results from triplicate
wells and three independent experiments.
Migration assays
Migration assays were performed in 48-well modified Boyden chambers
(Neuroprobe) using 8- m polycarbonate filters (Osmonics Inc.) coated on
both sides O/N with 10  g/ml of either VN or FN. 2.0   10
4 cells were
plated in serum-free Hb-DME containing 0.2% fatty acid–free BSA in qua-
druplicate wells and allowed to migrate in response to 10% FBS in the
lower chamber for 16 h. The upper side of the filter was scraped to re-
move nonmotile cells, fixed and stained with Diff-Quik
® (Dade-Behring) for
scanning, and quantification by densitometry using NIH Image software.
Flow cytometry
Suspended cells were incubated for 1 h on ice with 1  g of primary anti-
body per 3   10
5 cells, washed, and counterstained with Alexa-488
and/or R-PE–conjugated secondary antibodies (Molecular Probes). To
cluster mS1, cells in suspension were incubated with 1  g/ml mAb 281.2
(or mAb KY8.2 as an IgG control) for 15 min at 37 C, washed, and incu-
bated with a 5  g/ml of goat anti–rat IgG secondary (Jackson ImmunoRe-
search Laboratories) for an additional 15 min before staining and scan-
ning on a FACSCalibur benchtop cytometer (BD Biosciences). Cell scatter
and propidium iodide (Sigma-Aldrich; 1  g/sample) staining profiles
were used to gate live, single-cell events for data analysis. Cells were
sorted under sterile conditions on a triple-laser FACSVantage SE equipped
with the FACSDiVa digital electronics analyzer.
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